Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 65.66 USD 1.02% Market Closed
Market Cap: 12.5B USD
Have any thoughts about
Biomarin Pharmaceutical Inc?
Write Note

Wall Street
Price Targets

BMRN Price Targets Summary
Biomarin Pharmaceutical Inc

Wall Street analysts forecast BMRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMRN is 98.93 USD with a low forecast of 65.65 USD and a high forecast of 133.35 USD.

Lowest
Price Target
65.65 USD
0% Downside
Average
Price Target
98.93 USD
51% Upside
Highest
Price Target
133.35 USD
103% Upside

BMRN Last Price Targets
Biomarin Pharmaceutical Inc

The latest public price target was made on Oct 30, 2024 by David Lebowitz from Citigroup , who expects BMRN stock to rise by 23% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Lebowitz
Citigroup
81 USD
Upside 23%
1 month ago
Oct 30, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Citi
StreetInsider
Olivia Brayer
Cantor Fitzgerald
90 USD
Upside 37%
1 month ago
Oct 30, 2024
BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
TheFly
Jack Allen
Robert W. Baird
65 USD
Downside 1%
1 month ago
Oct 30, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $65 at Baird
StreetInsider
Danielle Brill
Raymond James
79 USD
Upside 20%
2 months ago
Oct 10, 2024
BioMarin reinstated with an Outperform at Raymond James
TheFly
Gena Wang
Barclays
86 USD
Upside 31%
2 months ago
Oct 4, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $86 at Barclays
StreetInsider
David Lebowitz
Citigroup
93 USD
Upside 42%
3 months ago
Sep 18, 2024
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Kostas Biliouris
BMO Capital
115 USD
Upside 75%
3 months ago
Sep 17, 2024
BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
StreetInsider
William Pickering
Bernstein
90 USD
Upside 37%
3 months ago
Sep 17, 2024
BioMarin price target lowered to $90 from $116 at Bernstein
TheFly
George Farmer
Scotiabank
78 USD
Upside 19%
3 months ago
Sep 17, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $78 at Scotiabank
StreetInsider
Joon Lee
Truist Financial
90 USD
Upside 37%
3 months ago
Sep 17, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $90 at Truist Securities
StreetInsider
Gena Wang
Barclays
110 USD
Upside 68%
3 months ago
Sep 16, 2024
Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Christopher Raymond
Raymond James
122 USD
Upside 86%
3 months ago
Sep 5, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $122 at Piper Sandler
StreetInsider
George Farmer
Scotiabank
95 USD
Upside 45%
3 months ago
Sep 5, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Scotiabank
StreetInsider
Christopher Raymond
Raymond James
107 USD
Upside 63%
3 months ago
Aug 27, 2024
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Paul Matteis
Stifel Nicolaus
115 USD
Upside 75%
4 months ago
Aug 21, 2024
BioMarin price target raised to $115 from $112 at Stifel
TheFly
William Pickering
Tudor Pickering
110 USD
Upside 68%
4 months ago
Aug 20, 2024
Bernstein SocGen Group Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
StreetInsider
Whitney Ijem
Canaccord Genuity
93 USD
Upside 42%
4 months ago
Aug 6, 2024
BioMarin price target raised to $93 from $89 at Canaccord
TheFly
Cory Kasimov
Evercore ISI
115 USD
Upside 75%
4 months ago
Aug 6, 2024
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Benzinga
Paul Matteis
Stifel Nicolaus
112 USD
Upside 71%
4 months ago
Aug 6, 2024
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Benzinga
Mohit Bansal
Wells Fargo
115 USD
Upside 75%
5 months ago
Jun 27, 2024
BioMarin price target raised to $115 from $111 at Wells Fargo
TheFly
William Pickering
Tudor Pickering
91 USD
Upside 39%
6 months ago
Jun 4, 2024
BridgeBio data incrementally negative for BioMarin, says Bernstein
TheFly
Jack Allen
Robert W. Baird
72 USD
Upside 10%
7 months ago
May 17, 2024
Baird Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Neutral
StreetInsider
Cory Kasimov
Evercore ISI
113 USD
Upside 72%
7 months ago
May 13, 2024
BioMarin initiated with an Outperform at Evercore ISI
TheFly
George Farmer
Scotiabank
85 USD
Upside 29%
7 months ago
Apr 25, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
StreetInsider
Eliana Merle
UBS
119 USD
Upside 81%
8 months ago
Apr 22, 2024
UBS Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Kostas Biliouris
BMO Capital
102 USD
Upside 55%
1 year ago
Jul 5, 2023
BMO Capital Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
StreetInsider
Show More Price Targets
Show Less Price Targets
David Lebowitz
Citigroup
Price Target 81 USD
Upside/Downside 23%
View Source
Olivia Brayer
Cantor Fitzgerald
Price Target 90 USD
Upside/Downside 37%
View Source
Jack Allen
Robert W. Baird
Price Target 65 USD
Upside/Downside 1%
View Source
Danielle Brill
Raymond James
Price Target 79 USD
Upside/Downside 20%
View Source
Gena Wang
Barclays
Price Target 86 USD
Upside/Downside 31%
View Source
David Lebowitz
Citigroup
Price Target 93 USD
Upside/Downside 42%
View Source
Kostas Biliouris
BMO Capital
Price Target 115 USD
Upside/Downside 75%
View Source
William Pickering
Bernstein
Price Target 90 USD
Upside/Downside 37%
View Source
George Farmer
Scotiabank
Price Target 78 USD
Upside/Downside 19%
View Source
Joon Lee
Truist Financial
Price Target 90 USD
Upside/Downside 37%
View Source
Gena Wang
Barclays
Price Target 110 USD
Upside/Downside 68%
View Source
Christopher Raymond
Raymond James
Price Target 122 USD
Upside/Downside 86%
View Source
George Farmer
Scotiabank
Price Target 95 USD
Upside/Downside 45%
View Source
Christopher Raymond
Raymond James
Price Target 107 USD
Upside/Downside 63%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 115 USD
Upside/Downside 75%
View Source
William Pickering
Tudor Pickering
Price Target 110 USD
Upside/Downside 68%
View Source
Whitney Ijem
Canaccord Genuity
Price Target 93 USD
Upside/Downside 42%
View Source
Cory Kasimov
Evercore ISI
Price Target 115 USD
Upside/Downside 75%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 112 USD
Upside/Downside 71%
View Source
Mohit Bansal
Wells Fargo
Price Target 115 USD
Upside/Downside 75%
View Source
William Pickering
Tudor Pickering
Price Target 91 USD
Upside/Downside 39%
View Source
Jack Allen
Robert W. Baird
Price Target 72 USD
Upside/Downside 10%
View Source
Cory Kasimov
Evercore ISI
Price Target 113 USD
Upside/Downside 72%
View Source
George Farmer
Scotiabank
Price Target 85 USD
Upside/Downside 29%
View Source
Eliana Merle
UBS
Price Target 119 USD
Upside/Downside 81%
View Source
Kostas Biliouris
BMO Capital
Price Target 102 USD
Upside/Downside 55%
View Source
Show More Price Targets
Show Less Price Targets
Biomarin Pharmaceutical Inc Competitors:
Price Targets
NTRA
Natera Inc
14% Upside
CMRX
Chimerix Inc
139% Upside
IMTX
Immatics NV
146% Upside
RCUS
Arcus Biosciences Inc
124% Upside
BVXP
Bioventix PLC
56% Upside
ABBV
Abbvie Inc
20% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
20% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
31% Upside

Revenue
Forecast

Revenue Estimate
Biomarin Pharmaceutical Inc

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 4 years is 11%.

13%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 4 years is 64%.

N/A
Past Growth
64%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Net Income
Forecast

Net Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 4 years is 60%.

N/A
Past Growth
60%
Estimated Growth
Estimates Accuracy
4%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMRN's stock price target?
Price Target
98.93 USD

According to Wall Street analysts, the average 1-year price target for BMRN is 98.93 USD with a low forecast of 65.65 USD and a high forecast of 133.35 USD.

What is Biomarin Pharmaceutical Inc's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 4 years is 11%.

What is Biomarin Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
64%

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 4 years is 64%.

What is Biomarin Pharmaceutical Inc's Net Income forecast?
Projected CAGR
60%

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 4 years is 60%.

Back to Top